FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies

FDA Extends Comment Period for Real-Time Clinical Trials Pilot

The FDA has extended the public comment period for its Real-Time Clinical Trials (RTCT) pilot and the associated Request for Information on AI-enabled optimization of early-phase trials. This move signals the agency's commitment to integrating AI into clinical trial oversight, with implications for drug development speed, cost, and regulatory strategy.

Key Takeaways

• The FDA pushed the FDA real-time clinical trials RFI comment deadline to June 29, 2026 — a 30-day extension from the original May 29 closure.
• The RFI specifically asks how AI-enabled technologies can improve the efficiency, speed, and quality of FDA decision-making in early-phase trials.
• Pharma BD teams and investors should treat the extension as a window to shape the regulatory framework for real-time data feeds and AI oversight, which could directly affect trial design costs and competitive positioning.
• The Rtct fda pilot allows the agency to receive direct data feeds from trials via cloud platforms, a structural change that may shorten review cycles and enable adaptive designs.

What Changed in the FDA’s Timeline?

On May 27, 2026, the FDA posted a notice in the Federal Register extending the comment period for the Request for Information (RFI) on the AI enabled Optimization of early phase clinical trials pilot program Request for Information until June 29, 2026. The original deadline was May 29. The RFI, first issued in April, seeks public input on scaling the Real-Time Clinical Trials (RTCT) pilot, which allows the agency to receive direct data feeds from clinical trials via cloud-based platforms. According to a GovExec report, the FDA will have “a direct data feed from a clinical trial, where the FDA will see what is happening, in the cloud.” The pilot builds on earlier efforts like the Stream SCLC trial — an example cited in the agency’s initial announcement — though the comment period extension gives industry stakeholders another month to weigh in on how AI can optimize oversight.

How Will AI Optimize Early-Phase Trials?

The RFI asks for input on how AI-enabled technologies can improve the efficiency, speed, and quality of FDA decision-making in early-phase trials. According to the Federal Register notice, the agency is interested in methods that use AI to analyze streaming trial data, flag safety signals in near-real time, and enable adaptive trial designs. The pilot program builds on the FDA’s earlier work with real-time data feeds, and the RFI covers topics like data privacy, algorithm transparency, and endpoint selection. For pharma teams, the key question is whether the FDA will ultimately require AI validation standards that match the rigor of traditional clinical data reviews — or create a faster lane for companies that invest in AI-enabled trial infrastructure. A recent JAMA Health Forum analysis noted that AI could “reduce costs, accelerate innovation, and unlock huge benefits to patients” by improving trial enrollment and real-world data analysis. The comment period provides a channel for sponsors to argue for practical validation pathways rather than overly burdensome requirements that could blunt the pilot’s impact.

Real-Time Data Feeds: A Structural Shift for Sponsors

The RTCT pilot is not just another FDA technology demonstration — it is a structural shift in how the agency interacts with trial data. Instead of waiting for locked databases and periodic submissions, the FDA can monitor safety and efficacy signals as they emerge. For pharmaceutical companies, that means less time spent on reconciliation and data cleaning, and more opportunity to run adaptive dose-finding or seamless Phase 1/2 designs. The AI enabled Optimization of early phase clinical trials pilot program Request for Information explicitly asks how AI can improve decision-making efficiency, speed, and quality. Sponsors that integrate AI tools for real-time analytics, natural language processing of adverse events, or predictive modeling of site performance could see faster regulatory feedback. But the flip side is that the FDA will also gain transparency into trial operations, potentially increasing scrutiny on data quality and enrollment practices. The pilot’s success will depend on whether the agency can handle the volume of incoming data without creating bottlenecks, and whether industry can trust the AI tools used to flag safety signals.

What Should Pharma BD Teams and Investors Watch for Next?

For business development and corporate strategy groups, the RTCT pilot represents a potential paradigm shift in how early-phase trials are conducted and reviewed. Real-time data access could shorten trial timelines, reduce costs, and enable more adaptive trial designs. Companies that invest in AI capabilities for trial optimization may gain a competitive edge in regulatory speed and data quality. Investors should watch for FDA guidance post-comment period, as clarity on AI validation and data standards will affect the risk profile of early-stage assets. Teams should consider submitting comments to influence the framework, particularly around data privacy, algorithm transparency, and endpoint selection. The extended comment period gives sponsors a concrete opportunity to shape the rules before they become final.

Another signal to track is whether the FDA will host a real time clinical trials industry day to discuss feedback before issuing formal guidance. Although not yet announced, such an event is typical for complex pilot programs and would provide additional clarity on the agency’s thinking. BD teams should also monitor parallel developments at EMA and other regulators, as the RTCT approach could become a global standard.

Frequently Asked Questions

Related coverage

• FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies
• Uncertain FDA Leadership Raises Stakes in Clinical Trials: A Strategic Overview
• FDA's Shifting Tides: Navigating Clinical Trials Amidst Regulatory Uncertainty